Physician profile
Zachary Wright
NPI 1497982029
$168,297.64
in general payments reported to CMS, 2019-2025
46 companies · $12K in 2025
The $12K reported for 2025 was more than what 82% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2021: $156 · 2022: $32K · 2023: $55K · 2024: $22K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $79K · Food and Beverage: $5,445 · Travel and Lodging: $3,838 · Education: $15.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,818.00 |
| Food and Beverage | $5,445.33 |
| Travel and Lodging | $3,838.27 |
| Education | $15.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $99,965.08 | 2022-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $63,395.16 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $1,202.73 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $584.45 | 2021-2025 | |
| Celgene Corporation | $363.15 | 2022-2025 | Reblozyl, Pomalyst, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $266.78 | 2021-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $263.46 | 2022-2025 | Darzalex, Tecvayli, Carvykti |
| Incyte Corporation | $238.71 | 2019-2025 | Monjuvi, Zynyz, Jakafi |
| Daiichi Sankyo INC. | $179.13 | 2022-2025 | Enhertu, Datroway, Vanflyta |
| Abbvie INC. | $163.64 | 2019-2025 | |
| Genentech USA, INC. | $161.32 | 2019-2025 | Polivy, Lunsumio, Columvi |
| Amgen INC. | $156.87 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $136.99 | 2022-2025 | Calquence, Enhertu, Imfinzi |
| Eisai INC. | $132.06 | 2021-2025 | |
| Glaxosmithkline, LLC. | $85.78 | 2023-2025 | Jemperli, Ojjaara, Zejula |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.